Impact of alternative approaches to accelerated measles control: experience in the African region, 1996-2002
- PMID: 12721884
- DOI: 10.1086/368272
Impact of alternative approaches to accelerated measles control: experience in the African region, 1996-2002
Abstract
From 1996 to 2000, several African countries accelerated measles control by providing a second opportunity for measles vaccine through supplemental campaigns. Fifteen countries completed campaigns in children aged 9 months to 14 years. Seven countries completed campaigns in children aged 9-59 months. In almost all countries that conducted campaigns in children aged 9 months to 14 years, measles deaths were reduced to near zero. In six countries, near-zero measles mortality has been maintained for 4-6 years. Supplemental immunization in children <5 years old was only partially effective (range, 0-67%) in reducing mortality. Measles cases decreased by 50% when routine vaccination coverage increased from 50% to 80%. Initial measles campaigns in children aged 9 months to 14 years, follow-up campaigns in those aged 9-59 months every 3-5 years, and increased routine coverage to 80% will be needed to reduce and maintain measles deaths in African countries at near zero.
Similar articles
-
Impact of mass measles campaigns among children less than 5 years old in Uganda.J Infect Dis. 2003 May 15;187 Suppl 1:S63-8. doi: 10.1086/368026. J Infect Dis. 2003. PMID: 12721893
-
Progress toward measles control - African region, 2001-2008.MMWR Morb Mortal Wkly Rep. 2009 Sep 25;58(37):1036-41. MMWR Morb Mortal Wkly Rep. 2009. PMID: 19779399
-
Measles mortality reduction--West Africa, 1996-2002.MMWR Morb Mortal Wkly Rep. 2004 Jan 23;53(2):28-30. MMWR Morb Mortal Wkly Rep. 2004. PMID: 14737060
-
Two-dose measles vaccination schedules.Bull World Health Organ. 1993;71(3-4):421-8. Bull World Health Organ. 1993. PMID: 8324862 Free PMC article. Review.
-
Progress toward measles eradication in the region of the Americas.J Infect Dis. 2003 May 15;187 Suppl 1:S102-10. doi: 10.1086/368032. J Infect Dis. 2003. PMID: 12721900 Review.
Cited by
-
Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.J Virol. 2005 Aug;79(15):9854-61. doi: 10.1128/JVI.79.15.9854-9861.2005. J Virol. 2005. PMID: 16014946 Free PMC article.
-
A 'post-honeymoon' measles epidemic in Burundi: mathematical model-based analysis and implications for vaccination timing.PeerJ. 2016 Sep 15;4:e2476. doi: 10.7717/peerj.2476. eCollection 2016. PeerJ. 2016. PMID: 27672515 Free PMC article.
-
Evolution and Contribution of a Global Partnership against Measles and Rubella, 2001-2023.Vaccines (Basel). 2024 Jun 20;12(6):693. doi: 10.3390/vaccines12060693. Vaccines (Basel). 2024. PMID: 38932422 Free PMC article.
-
Assessment of measles immunity among infants in Maputo City, Mozambique.BMC Public Health. 2008 Nov 12;8:386. doi: 10.1186/1471-2458-8-386. BMC Public Health. 2008. PMID: 19014485 Free PMC article.
-
Possible interruption of measles virus transmission, Uganda, 2006-2009.Emerg Infect Dis. 2011 Jan;17(1):110-3. doi: 10.3201/eid1701.100753. Emerg Infect Dis. 2011. PMID: 21192868 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical